Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840289 | 0.92 | USP2 (0.42) | PARP1USP2SMN1; SMN2NR1H2PRMT5 | |
| SCHEMBL4840657 | 0.92 | USP2 (0.42) | PARP1USP2SMN1; SMN2NR1H2PRMT5 | |
| SCHEMBL4835258 | 0.92 | USP2 (0.42) | PARP1USP2SMN1; SMN2NR1H2PRMT5 | |
| SCHEMBL4835243 | 0.92 | USP2 (0.42) | PARP1USP2SMN1; SMN2NR1H2PRMT5 | |
| SCHEMBL4838964 | 0.92 | USP2 (0.42) | PARP1USP2SMN1; SMN2NR1H2PRMT5 | |
| SCHEMBL21713897 | 0.85 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10NR1H2 | |
| SCHEMBL30111484 | 0.83 | NR1H2 (0.46) | PARP1USP2SMN1; SMN2HSD17B10NR1H2 | |
| SCHEMBL28490941 | 0.83 | PARP1 (0.48) | PARP1USP2SMN1; SMN2HSD17B10NR1H2 | |
| SCHEMBL1183970 | 0.83 | NR1H2 (0.46) | PARP1USP2SMN1; SMN2HSD17B10NR1H2 | |
| SCHEMBL4844818 | 0.81 | PARP1 (0.39) | PARP1USP2SMN1; SMN2HSD17B10NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | PARP1 2330/4885USP2 3027/4885SMN1; SMN2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.